{"count": 25, "results": [{"_id": "37023313", "pmid": 37023313, "title": "Effects of Valsartan and Amlodipine Tablets Combined with alpha-Lipoic Acid on T-AOC, IL-6 and beta2-MG Levels in Patients with Diabetic Nephropathy.", "journal": "Altern Ther Health Med", "authors": ["Su F", "Xia Q"], "date": "2023-04-07T00:00:00Z", "meta_date_publication": "2023 Apr 7", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50258.87, "text_hl": "Effects of @CHEMICAL_Valsartan @CHEMICAL_MESH:D000068756 @@@Valsartan@@@ and @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@Amlodipine@@@ Tablets Combined with @CHEMICAL_Thioctic_Acid @CHEMICAL_MESH:D008063 @@@alpha-Lipoic Acid@@@ on T-AOC, @GENE_IL6 @GENE_3569 @@@IL-6@@@ and beta2-MG Levels in @SPECIES_9606 @@@Patients@@@ with @<m>DISEASE_Diabetic_Nephropathies</m> @DISEASE_MESH:D003928 @@@Diabetic Nephropathy@@@.", "citations": {"NLM": "Su F, Xia Q. Effects of Valsartan and Amlodipine Tablets Combined with alpha-Lipoic Acid on T-AOC, IL-6 and beta2-MG Levels in Patients with Diabetic Nephropathy. Altern Ther Health Med. 2023 Apr 7;():. PMID: 37023313", "BibTeX": "@article{37023313, title={Effects of Valsartan and Amlodipine Tablets Combined with alpha-Lipoic Acid on T-AOC, IL-6 and beta2-MG Levels in Patients with Diabetic Nephropathy.}, author={Su F and Xia Q}, journal={Altern Ther Health Med}}"}}, {"_id": "19450066", "pmid": 19450066, "title": "Amlodipine: a pharmacoeconomic review.", "journal": "J Med Econ", "authors": ["de Portu S", "Mantovani LG"], "date": "2009-03-01T00:00:00Z", "doi": "10.3111/13696990802525266", "meta_date_publication": "2009 Mar", "meta_volume": "12", "meta_issue": "1", "meta_pages": "60-8", "score": 50074.938, "text_hl": "METHODS: A review of the available outcome trials evaluating the clinical effectiveness of @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ in @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensive@@@ @SPECIES_9606 @@@patients@@@ or in @SPECIES_9606 @@@patients@@@ with @DISEASE_Coronary_Artery_Disease @DISEASE_MESH:D003324 @@@CAD@@@ or @<m>DISEASE_Diabetic_Nephropathies</m> @DISEASE_MESH:D003928 @@@diabetic nephropathy@@@ was carried out to identify pharmacoeconomic studies that quantified the economic impact of using @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ instead of another treatment. ", "citations": {"NLM": "de Portu S, Mantovani LG. Amlodipine: a pharmacoeconomic review. J Med Econ. 2009 Mar;12(1):60-8. PMID: 19450066", "BibTeX": "@article{19450066, title={Amlodipine: a pharmacoeconomic review.}, author={de Portu S and Mantovani LG}, journal={J Med Econ}, volume={12}, number={1}, pages={60-8}}"}}, {"_id": "16231503", "pmid": 16231503, "title": "[Pharmacogenetics of angiotensin system in non diabetic nephropathy].", "journal": "Nefrologia", "authors": ["Coto E", "Marín R", "Alvarez V", "Praga M", "Fernández Andrade C", "Arias M", "Poveda R", "Vallés M", "Galcerán JM", "Luño J", "Rivera F", "Campistol JM"], "date": "2005-01-01T00:00:00Z", "meta_date_publication": "2005", "meta_volume": "25", "meta_issue": "4", "meta_pages": "381-6", "score": 50071.46, "text_hl": "METHODS: A total of 71 non-@<m>DISEASE_Diabetic_Nephropathies</m> @DISEASE_MESH:D003928 @@@diabetic chronic nephropathy@@@ @SPECIES_9606 @@@patients@@@ were treated with @CHEMICAL_Losartan @CHEMICAL_MESH:D019808 @@@losartan@@@ (n = 37) or @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ (n = 34). ", "citations": {"NLM": "Coto E, Marín R, Alvarez V, Praga M, Fernández Andrade C, Arias M, Poveda R, Vallés M, Galcerán JM, Luño J, Rivera F, Campistol JM. [Pharmacogenetics of angiotensin system in non diabetic nephropathy]. Nefrologia. 2005;25(4):381-6. PMID: 16231503", "BibTeX": "@article{16231503, title={[Pharmacogenetics of angiotensin system in non diabetic nephropathy].}, author={Coto E and Marín R and Alvarez V and Praga M and Fernández Andrade C and Arias M and Poveda R and Vallés M and Galcerán JM and Luño J and Rivera F and Campistol JM}, journal={Nefrologia}, volume={25}, number={4}, pages={381-6}}"}}, {"_id": "15855214", "pmid": 15855214, "title": "Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies.", "journal": "Nephrol Dial Transplant", "authors": ["Palmer AJ", "Tucker DM", "Valentine WJ", "Roze S", "Gabriel S", "Cordonnier DJ"], "date": "2005-06-01T00:00:00Z", "doi": "10.1093/ndt/gfh802", "meta_date_publication": "2005 Jun", "meta_volume": "20", "meta_issue": "6", "meta_pages": "1103-9", "score": 50067.523, "text_hl": "In each, the same pharmacoeconomic model was adapted using country-specific data to project and evaluate the clinical and cost outcomes of the treatment arms of the @CHEMICAL_Irbesartan @CHEMICAL_MESH:D000077405 @@@Irbesartan@@@ in @<m>DISEASE_Diabetic_Nephropathies</m> @DISEASE_MESH:D003928 @@@Diabetic Nephropathy@@@ Trial (IDNT) (@CHEMICAL_Irbesartan @CHEMICAL_MESH:D000077405 @@@irbesartan@@@, @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ or standard blood pressure control). ", "citations": {"NLM": "Palmer AJ, Tucker DM, Valentine WJ, Roze S, Gabriel S, Cordonnier DJ. Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrol Dial Transplant. 2005 Jun;20(6):1103-9. PMID: 15855214", "BibTeX": "@article{15855214, title={Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies.}, author={Palmer AJ and Tucker DM and Valentine WJ and Roze S and Gabriel S and Cordonnier DJ}, journal={Nephrol Dial Transplant}, volume={20}, number={6}, pages={1103-9}}"}}, {"_id": "9870472", "pmid": 9870472, "title": "Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy.", "journal": "Nephrol Dial Transplant", "authors": ["Holdaas H", "Hartmann A", "Berg KJ", "Lund K", "Fauchald P"], "date": "1998-12-01T00:00:00Z", "doi": "10.1093/ndt/13.12.3096", "meta_date_publication": "1998 Dec", "meta_volume": "13", "meta_issue": "12", "meta_pages": "3096-102", "score": 50066.562, "text_hl": "Renal effects of @CHEMICAL_Losartan @CHEMICAL_MESH:D019808 @@@losartan@@@ and @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ in @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensive@@@ @SPECIES_9606 @@@patients@@@ with non-@<m>DISEASE_Diabetic_Nephropathies</m> @DISEASE_MESH:D003928 @@@diabetic nephropathy@@@.", "citations": {"NLM": "Holdaas H, Hartmann A, Berg KJ, Lund K, Fauchald P. Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transplant. 1998 Dec;13(12):3096-102. PMID: 9870472", "BibTeX": "@article{9870472, title={Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy.}, author={Holdaas H and Hartmann A and Berg KJ and Lund K and Fauchald P}, journal={Nephrol Dial Transplant}, volume={13}, number={12}, pages={3096-102}}"}}, {"_id": "21772148", "pmid": 21772148, "title": "Amlodipine-induced toxic epidermal necrolysis.", "journal": "J Burn Care Res", "authors": ["Baetz BE", "Patton ML", "Guilday RE", "Reigart CL", "Ackerman BH"], "date": "2011-09-01T00:00:00Z", "doi": "10.1097/BCR.0b013e31822ac7be", "meta_date_publication": "2011 Sep-Oct", "meta_volume": "32", "meta_issue": "5", "meta_pages": "e158-60", "score": 50065.434, "text_hl": "The objective of this study is to report a case of @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@-induced dermatotoxicity following treatment for @<m>DISEASE_Diabetic_Nephropathies</m> @DISEASE_MESH:D003928 @@@diabetic nephropathy@@@. ", "citations": {"NLM": "Baetz BE, Patton ML, Guilday RE, Reigart CL, Ackerman BH. Amlodipine-induced toxic epidermal necrolysis. J Burn Care Res. 2011 Sep-Oct;32(5):e158-60. PMID: 21772148", "BibTeX": "@article{21772148, title={Amlodipine-induced toxic epidermal necrolysis.}, author={Baetz BE and Patton ML and Guilday RE and Reigart CL and Ackerman BH}, journal={J Burn Care Res}, volume={32}, number={5}, pages={e158-60}}"}}, {"_id": "14968145", "pmid": 14968145, "title": "Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada.", "journal": "Can J Cardiol", "authors": ["Coyle D", "Rodby RA"], "date": "2004-01-01T00:00:00Z", "meta_date_publication": "2004 Jan", "meta_volume": "20", "meta_issue": "1", "meta_pages": "71-9", "score": 50063.805, "text_hl": "Economic evaluation of the use of @CHEMICAL_Irbesartan @CHEMICAL_MESH:D000077405 @@@irbesartan@@@ and @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ in the treatment of @<m>DISEASE_Diabetic_Nephropathies</m> @DISEASE_MESH:D003928 @@@diabetic nephropathy@@@ in @SPECIES_9606 @@@patients@@@ with @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ in Canada.", "citations": {"NLM": "Coyle D, Rodby RA. Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. Can J Cardiol. 2004 Jan;20(1):71-9. PMID: 14968145", "BibTeX": "@article{14968145, title={Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada.}, author={Coyle D and Rodby RA}, journal={Can J Cardiol}, volume={20}, number={1}, pages={71-9}}"}}, {"_id": "15327403", "pmid": 15327403, "title": "Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes.", "journal": "Kidney Int", "authors": ["Ma G", "Allen TJ", "Cooper ME", "Cao Z"], "date": "2004-09-01T00:00:00Z", "doi": "10.1111/j.1523-1755.2004.00859.x", "meta_date_publication": "2004 Sep", "meta_volume": "66", "meta_issue": "3", "meta_pages": "1090-8", "score": 50063.316, "text_hl": "These findings suggest that CCBs may be useful in preventing pathologic injury in the @<m>DISEASE_Diabetic_Nephropathies</m> @DISEASE_MESH:D003928 @@@diabetic kidney@@@.", "citations": {"NLM": "Ma G, Allen TJ, Cooper ME, Cao Z. Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes. Kidney Int. 2004 Sep;66(3):1090-8. PMID: 15327403", "BibTeX": "@article{15327403, title={Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes.}, author={Ma G and Allen TJ and Cooper ME and Cao Z}, journal={Kidney Int}, volume={66}, number={3}, pages={1090-8}}"}}, {"_id": "16015004", "pmid": 16015004, "title": "A prospective open-label randomised trial of quinapril and/or amlodipine in progressive non-diabetic renal failure.", "journal": "Nephron Clin Pract", "authors": ["MacGregor MS", "Deighan CJ", "Rodger RS", "Boulton-Jones JM"], "date": "2005-01-01T00:00:00Z", "doi": "10.1159/000086714", "meta_date_publication": "2005", "meta_volume": "101", "meta_issue": "3", "meta_pages": "c139-49", "score": 50058.3, "text_hl": "METHODS: 73 @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensive@@@ @SPECIES_9606 @@@patients@@@ with progressive @<m>DISEASE_Diabetic_Nephropathies</m> @DISEASE_MESH:D003928 @@@non-diabetic nephropathies@@@ were prospectively randomised to open-label @CHEMICAL_Quinapril @CHEMICAL_MESH:D000077583 @@@quinapril@@@ (Q, n = 28), @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ (A, n = 28) or both drugs (Q&A, n = 17). ", "citations": {"NLM": "MacGregor MS, Deighan CJ, Rodger RS, Boulton-Jones JM. A prospective open-label randomised trial of quinapril and/or amlodipine in progressive non-diabetic renal failure. Nephron Clin Pract. 2005;101(3):c139-49. PMID: 16015004", "BibTeX": "@article{16015004, title={A prospective open-label randomised trial of quinapril and/or amlodipine in progressive non-diabetic renal failure.}, author={MacGregor MS and Deighan CJ and Rodger RS and Boulton-Jones JM}, journal={Nephron Clin Pract}, volume={101}, number={3}, pages={c139-49}}"}}, {"_id": "9855027", "pmid": 9855027, "title": "Optimizing antihypertensive therapy in patients with diabetic nephropathy.", "journal": "J Hypertens Suppl", "authors": ["Ritz E", "Rychlík I", "Miltenberger-Miltenyi G"], "date": "1998-09-01T00:00:00Z", "meta_date_publication": "1998 Sep", "meta_volume": "16", "meta_issue": "7", "meta_pages": "S17-22", "score": 50058.24, "text_hl": "The @CHEMICAL_Irbesartan @CHEMICAL_MESH:D000077405 @@@Irbesartan@@@ @<m>DISEASE_Diabetic_Nephropathies</m> @DISEASE_MESH:D003928 @@@Diabetic Nephropathy@@@ Trial (IDNT) has already enrolled approximately 85% of the proposed 1650 @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@NIDDM@@@ @SPECIES_9606 @@@patients@@@ to be randomly assigned to placebo, @CHEMICAL_Irbesartan @CHEMICAL_MESH:D000077405 @@@irbesartan@@@ or @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@. ", "citations": {"NLM": "Ritz E, Rychlík I, Miltenberger-Miltenyi G. Optimizing antihypertensive therapy in patients with diabetic nephropathy. J Hypertens Suppl. 1998 Sep;16(7):S17-22. PMID: 9855027", "BibTeX": "@article{9855027, title={Optimizing antihypertensive therapy in patients with diabetic nephropathy.}, author={Ritz E and Rychlík I and Miltenberger-Miltenyi G}, journal={J Hypertens Suppl}, volume={16}, number={7}, pages={S17-22}}"}}]}